Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)

SHA:688566 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	810.49	781.43	847.52	694.87	903.9	1,025
Short-Term Investments	10.63	31.04	-	-	-	-
Trading Asset Securities	116.02	37.03	56	35	90	200
Cash & Short-Term Investments	937.14	849.51	903.52	729.87	993.9	1,225
Cash Growth	5.45%	-5.98%	23.79%	-26.57%	-18.87%	-4.84%
Accounts Receivable	341.77	366.28	365.92	369.15	216.21	146.6
Other Receivables	0.51	1.12	0.05	0.03	0.02	-
Receivables	342.28	367.4	365.97	369.17	216.23	146.6
Inventory	39.79	34.07	30.7	29.51	32.66	31.83
Other Current Assets	4.16	3.59	4.25	2.59	13.98	2.62
Total Current Assets	1,323	1,255	1,304	1,131	1,257	1,406
Property, Plant & Equipment	1,063	1,031	986.86	832.49	552.21	271.51
Long-Term Investments	76.45	231.89	110.16	126.19	61.74	56.63
Goodwill	35.33	35.33	-	-	-	-
Other Intangible Assets	56.58	58.03	56.69	58.2	59.74	61.28
Long-Term Deferred Tax Assets	25.18	22.64	17.93	16.13	15.59	11.72
Long-Term Deferred Charges	67.37	59.74	32.14	1.13	2.18	3.25
Other Long-Term Assets	235.01	24.23	19.33	44.38	16.34	8.21
Total Assets	2,882	2,717	2,528	2,210	1,965	1,819

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	66.05	74.29	97.15	91.22	101.67	69.92
Accrued Expenses	20.87	51.32	45.73	86.79	53.49	35.3
Short-Term Debt	7.05	16.52	20.83	9.91	-	-
Current Income Taxes Payable	36.25	7.71	2.01	0.19	6.09	5.19
Current Unearned Revenue	8.14	6.4	0.95	1.81	3.42	1.51
Other Current Liabilities	87.3	20.78	18.53	20.39	16.69	12.14
Total Current Liabilities	225.66	177.01	185.19	210.31	181.36	124.06
Long-Term Debt	-	2.2	-	-	-	-
Long-Term Unearned Revenue	60.94	58.39	58.59	59.04	58.85	59.7
Long-Term Deferred Tax Liabilities	2.78	3.23	3.25	3.25	3.4	-
Other Long-Term Liabilities	26.64	26.64	26.64	26.64	26.64	26.64
Total Liabilities	316.03	267.47	273.68	299.25	270.24	210.4

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	201.1	199.43	199.43	189.08	186.94	186.94
Additional Paid-In Capital	1,370	1,323	1,299	1,082	1,042	1,021
Retained Earnings	979.02	907.68	749.77	633.4	459.17	394.24
Comprehensive Income & Other	0.14	0.01	-	-	-	-
Total Common Equity	2,550	2,430	2,249	1,905	1,688	1,602
Minority Interest	15.9	19.6	5.23	5.58	5.9	6.31
Shareholders' Equity	2,566	2,450	2,254	1,910	1,694	1,608
Total Liabilities & Equity	2,882	2,717	2,528	2,210	1,965	1,819

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7.05	18.72	20.83	9.91	-	-
Net Cash (Debt)	930.08	830.79	882.69	719.96	993.9	1,225
Net Cash Growth	7.31%	-5.88%	22.60%	-27.56%	-18.87%	-4.84%
Net Cash Per Share	4.64	4.16	4.55	3.84	5.33	6.50
Filing Date Shares Outstanding	201.1	199.43	199.43	189.08	186.94	186.94
Total Common Shares Outstanding	201.1	199.43	199.43	189.08	186.94	186.94
Working Capital	1,098	1,078	1,119	920.84	1,075	1,282
Book Value Per Share	12.68	12.18	11.28	10.07	9.03	8.57
Tangible Book Value	2,458	2,337	2,192	1,847	1,629	1,541
Tangible Book Value Per Share	12.22	11.72	10.99	9.77	8.71	8.24
Buildings	-	312.04	142.66	142.66	142.52	142.52
Machinery	-	99.21	75.26	74.81	73.37	72.78
Construction In Progress	-	784.03	917.62	754.62	466.36	175.48

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error